The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

BACKGROUND: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez-Fonseca, Paula, Foy, Victoria, Raby, Sophie, Carmona-Bayonas, Alberto, Macía-Rivas, Lola, Arrazubi, Virginia, Cacho Lavin, Diego, Hernandez San Gil, Raquel, Custodio, Ana, Cano, Juana María, Fernández Montes, Ana, Mirallas, Oriol, Macias Declara, Ismael, Vidal Tocino, Rosario, Visa, Laura, Limón, María Luisa, Pimentel, Paola, Martínez Lago, Nieves, Sauri, Tamara, Martín Richard, Marta, Mangas, Monserrat, Gil Raga, Mireia, Calvo, Aitana, Reguera, Pablo, Granja, Mónica, Martín Carnicero, Alfonso, Hernández Pérez, Carolina, Cerdá, Paula, Gomez Gonzalez, Lucía, Garcia Navalon, Francisco, Pacheco Barcia, Vilma, Gutierrez Abad, David, Ruiz Martín, Maribel, Weaver, Jamie, Mansoor, Wasat, Gallego, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989382/
https://www.ncbi.nlm.nih.gov/pubmed/36895850
http://dx.doi.org/10.1177/17588359231157641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989382/
https://www.ncbi.nlm.nih.gov/pubmed/36895850
http://dx.doi.org/10.1177/17588359231157641

Ejemplares similares